Genetic Counseling and Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, and it arises from a complex mix of genetic and environmental factors. In recent years, advances in genetics have shed light on why AMD tends to run in families and how specific genes influence disease risk and progression. This has led to the emergence of genetic counseling and genetic testing as tools to help individuals understand their AMD risk. In this article, we will explore what genetic counseling is and how it applies to AMD, the genetic basis of AMD (including chances of inheriting it), the types of genetic tests available and what their results mean, the companies offering such tests, and how genetic insights are shaping current and future AMD prevention and treatment strategies.

What is Genetic Counseling?

Genetic counseling is a specialized healthcare service designed to help people understand and adapt to the impact of genetics on their health[1]. In a genetic counseling session, a genetic counselor (a professional with advanced training in medical genetics and counseling) will typically:

·      Assess Family and Medical History: They review the individual’s personal and family medical history to evaluate the likelihood of a genetic disorder or risk being present[2].

·      Provide Education: The counselor explains basic genetics (such as the role of DNA and genes) and how certain conditions can be inherited. They clarify complex concepts in simple terms – for example, using analogies like DNA being a “recipe book” for the body[3] – so that the person understands how genes might influence their health.

·      Discuss Testing Options: If appropriate, the counselor will inform the individual about available genetic tests, including what those tests can and cannot tell. They’ll cover the benefits, limitations, and potential outcomes of testing.

·      Facilitate Decision-Making: Genetic counselors support clients in making informed decisions about whether or not to proceed with genetic testing. This involves discussing the person’s values, concerns, and what they hope to gain from the information.

·      Interpret Results and Next Steps: If genetic testing is done, the counselor will interpret the results in the context of the individual’s situation. They explain what a positive, negative, or uncertain result means in practical terms. Importantly, they convey that genetic results often indicate probabilities or risk levels rather than certain predictions of disease.

·      Provide Emotional Support: Learning about genetic risks can be emotionally challenging. Genetic counselors are trained to provide psychosocial support, helping individuals cope with anxiety or difficult decisions. They ensure that patients do not feel alone in the process of understanding their genetic information[1].

Overall, the purpose of genetic counseling is to empower individuals with credible information and guidance so they can make informed choices regarding their health or family planning. This process addresses not only the medical facts, but also the psychological and familial implications of genetic information[1]. In the context of AMD, genetic counseling can be particularly useful for patients who have a family history of macular degeneration or who are considering genetic testing for AMD risk.

The Role of Genetic Counseling in AMD

Genetic counseling plays a valuable role in the management of age-related macular degeneration for individuals and families concerned about inherited risk. While AMD is primarily a disease of later life, knowing one’s genetic predisposition can influence how proactively one takes preventive actions and monitors eye health. A genetic counselor can guide patients through this process in several ways:

• Risk Assessment for Families: If you have a close relative (parent or sibling) with AMD, a counselor can help estimate your own risk based on family history and, if available, genetic test results. Family history is a significant risk factor – having an affected parent or sibling roughly doubles one’s chances of developing AMD (estimated around a 50% risk if a first-degree relative has AMD)[4]. Genetic counseling can help put this figure into perspective for you and your family. Counselors often explain that AMD’s inheritance is not straightforward dominant or recessive, but rather “polygenic” (involving many genes) and influenced by environment. This means even a high genetic risk does not guarantee disease, which can be reassuring information to families[5].
• Interpreting Genetic Testing Results: If an individual undergoes genetic testing for AMD(discussed in detail later), a counselor is crucial in explaining what the results mean. For instance, suppose a test reveals that a person carries certain high-risk gene variants for AMD. A genetic counselor will clarify that this indicates an increased probability of developing AMD compared to someone without those variants – but it is not a diagnosis and does not mean one will definitely get the disease[6][7]. They will emphasize the importance of regular eye exams and modifiable lifestyle factors regardless of the result. Conversely, if a test suggests lower genetic risk, the counselor will caution that this is not a free pass – aging and other factors can still lead to AMD, so vigilance is still required[7]. In short, counselors ensure that results are understood as a risk spectrum and help prevent misinterpretation or false security.
• Guidance on Prevention and Lifestyle: Perhaps the most constructive part of genetic counseling for AMD is turning knowledge of risk into an action plan. For someone with elevated genetic susceptibility, the counselor (often in collaboration with ophthalmologists) will recommend evidence-based preventive measures. These include smoking cessation, healthy diet, exercise, weight control, and UV protection, which benefit everyone but are especially critical if you’re at higher risk[8][9]. They may also discuss the role of antioxidant vitamins and zinc (the AREDS supplements) if appropriate for the patient’s age and eye exam findings, while clarifying current medical guidance on their use. Notably, genetic counselors stay updated on evolving research – for example, they can explain the ongoing debate about whether certain genotypes respond differently to high-dose zinc in supplements[10]. They help patients make informed choices, such as continuing standard supplement recommendations versus adjusting them, based on the latest evidence and personalized risk.
• Emotional and Ethical Support: Learning that you carry high-risk genes for vision loss can be stressful. Genetic counselors help individuals cope with this anxiety by providing perspective (e.g. many people with risk genes never develop significant AMD changes[5]) and by outlining concrete steps to mitigate risk. They also address ethical questions, such as “Do I tell my children or siblings about our family’s genetic risk?” or “Should I consider genetic testing at a younger age?” These discussions ensure that individuals and families feel informed and supported rather than alarmed by genetic information.

In summary, genetic counseling in AMD serves to empower patients with knowledge about their inherited risk and to integrate that knowledge into a proactive eye health strategy. It bridges the gap between complex genetic science and practical patient care, helping people understand their risk and what they can do about it[11]. Especially for those with a strong family history of macular degeneration, consulting a genetic counselor can add personalized guidance beyond what a regular clinic visit might provide.

Genetic Basis of Age-Related Macular Degeneration

Age-related macular degeneration is a multifactorial disease, meaning it does not have a single cause but arises from a combination of genetic predisposition and environmental influences. On the genetic side, research has shown that hereditary factors account for a large portion of AMD risk – roughly 50% to as much as 70% of the risk is attributable to genetics[4][12]. This helps explain why AMD often seems to “run in families.” For example, identical twin studies have found a high concordance for AMD, and having an immediate family member with AMD greatly increases one’s own risk compared to someone with no family history[4].

Over the past two decades, scientists have made great progress in identifying specific genes and gene variants associated with AMD. AMD is not a classical inherited disease caused by one gene mutation; instead, it is influenced by many genetic variants, each contributing a small amount to overall risk (a profile sometimes summed up as a person’s “polygenic risk score”). To date, at least 34 distinct genetic loci (regions of the genome) harboring around 52 known variants have been significantly associated with AMD[12]. It is one of the most well-characterized complex diseases genetically, with more than 30 genes implicated in susceptibility[13]. Here are a few of the key genes and genetic factors in AMD and what they mean:

• Complement Pathway Genes (Immune System): The first major genetic breakthrough in AMD was the discovery that variants in the CFH gene (Complement Factor H) are linked to AMD. CFH helps regulate the complement system, a part of our immune defense. A common variant in CFH (called Y402H) impairs this regulation and is associated with substantially higher AMD risk[13][14]. In fact, CFH and related complement genes (such as C3, C2, CFB, CFI) are now known to be critical – changes in these genes can lead to an overactive inflammatory response in the retina, contributing to the damage seen in AMD. The CFH Y402H risk variant alone has a strong effect size; individuals carrying two copies have several-fold increased odds of AMD. Another important gene is C3, a complement component where certain variants (e.g. R102G) also raise risk. The overall theme is that dysregulation of the complement cascade (an immune pathway) is a major driver of AMD, which is why these genes are so influential[15].
• ARMS2/HTRA1 (Chromosome 10q26 region): The second powerhouse genetic locus in AMD is on chromosome 10, containing the ARMS2 gene (Age-Related Maculopathy Susceptibility 2) and the adjacent HTRA1 gene. A specific variant in ARMS2 (often noted as A69S) and/or regulatory variants near HTRA1 confer a high risk for AMD[16]. These genes’ exact biological roles in the retina are still being studied; ARMS2’s function remains somewhat mysterious, whereas HTRA1 is a protein that may affect the extracellular matrix and cellular debris clearance in the macula. Nonetheless, statistically, the ARMS2/HTRA1 locus is as significant as CFH in terms of impact – they are the two major genetic factors in AMD identified so far[13][17]. Carrying risk variants in both CFH and ARMS2 dramatically increases one’s likelihood of developing AMD, illustrating a cumulative effect of multiple genes.
• Other Notable Genes: Beyond these, many other genes contribute to risk. Variants in genes involved in cholesterol and lipid metabolism (for example, APOE, APOC1, LIPC) have been implicated, suggesting that how the eye handles fats and cholesterol influences AMD progression[15]. Genes related to the extracellular matrix and collagen (such as TIMP3, COL8A1) point to the importance of Bruch’s membrane and structural support of the retina. Genes in pathways of oxidative stress and angiogenesis (formation of new blood vessels) also appear in the AMD genetics literature[15]. For instance, a variant near the MMP9 gene (matrix metalloproteinase-9) has been linked specifically to neovascular (wet) AMD in some studies[17], making it one of the first genetic clues distinguishing wet vs. dry forms. It’s important to note that each of these factors by itself usually has a modest effect – it’s the combination that matters. A person who inherits several risk alleles from various genes can end up with a significantly elevated overall risk.
• Genetic Risk and Inheritance: The inheritance of AMD is complex. It doesn’t follow a clear Mendelian pattern (like one gene causing disease in a dominant or recessive way). Instead, it behaves like other common diseases (e.g. heart disease or diabetes) where many genes each nudge the risk up or down. So, one can inherit a predisposition to AMD rather than a guarantee. If a person has high-risk versions of many AMD-related genes, we could say they “inherited a susceptibility.” This is why family history is so predictive: close relatives share many of the same risk variants. As mentioned, having an affected parent or sibling means your genetic makeup likely includes some of those risk variants, translating to about a 2-3 times higher risk than someone with no family history[4]. However, it’s equally crucial to recognize that not everyone with a heavy genetic load gets AMD. Some people with “the worst” genetic profile might never develop more than mild retinal changes, especially if they avoid smoking and other harmful environmental exposures[6]. Conversely, someone with fewer risk genes could still get AMD in late age, particularly if they have poor lifestyle factors. Therefore, genetics is probabilistic for AMD. What is inherited is a predisposition, not a certain fate – a message genetic counselors stress to patients to keep them from fatalistic thinking.

In summary, AMD has a strong genetic component, with dozens of genes identified that together explain a large share of why some individuals are more prone to this disease[12]. The two most influential genetic factors are changes in the CFH gene (and other complement genes) and the ARMS2/HTRA1 region[13]. These discoveries have not only improved risk prediction but also pointed scientists toward biological pathways (like the complement system) that could be targeted for therapy. It’s an exciting example of how understanding genetics helps unravel the biology of a disease: in AMD, our genes spotlighted inflammation, immune regulation, and lipid metabolism as key players, which are now central to developing new treatments (discussed later). Importantly, even though you can’t change your genes, knowing about them can motivate changes in what you can control – which leads us to genetic testing and how people use this information.

Genetic Testing for AMD: What Tests Are Available?

Given the array of genes involved in AMD, a logical question is whether we can test for these genes to determine an individual’s risk. The answer is yes – there are genetic tests that assess AMD risk – but the landscape of AMD genetic testing is nuanced. Unlike a simple blood test for a single mutation (as is done for some inherited diseases), AMD genetic testing usually involves looking for multiple genetic markers (variants) and then combining them into a risk score or category. Here we’ll review the types of genetic tests available for AMD, what they entail, and who offers them.

Types of Genetic Tests for AMD: Most AMD genetic tests are done on a DNA sample from cheek swab or saliva (or sometimes blood). They generally use one of two technologies:

·      Targeted genotyping: This approach checks for specific known variants in AMD-related genes. For example, a targeted test might look specifically at the presence or absence of the risk alleles in CFH and ARMS2, plus a handful of others. This is quicker and cheaper than sequencing. Many early tests (and direct-to-consumer tests) use this method.

·      Genetic panel sequencing: A more comprehensive approach is to sequence a panel of genes known to be associated with macular diseases. One company, for instance, offers an AMD NGS (Next-Generation Sequencing) panel that sequences multiple genes associated with macular degeneration. This can pick up rare variants as well, though in AMD common variants are the main players. Sequencing is more expensive and typically done through clinical laboratories or research studies rather than consumer kits.

Commercial AMD Genetic Testing Services: Over the past decade, several companies and labs have developed genetic tests specifically for AMD risk assessment. Below are some of the prominent ones (global offerings limited to AMD testing):

• ArcticDx – Macula Risk® PGx: Macula Risk (offered by ArcticDx, a molecular diagnostics company based in Toronto, Canada) was one of the first widely available AMD genetic tests[18]. It analyzes markers in multiple genes – initially focusing on variants in CFH, ARMS2, C3, and a mitochondrial gene ND2, combined with the patient’s smoking history[19]. The test stratifies a patient into a risk category for progressing to advanced AMD, ranging from category 1 (low risk) up to category 5 (highest risk)[19]. A later version, Macula Risk PGx, expanded the number of genetic markers (15 variants across 12 loci, as of one report) and also incorporates personal factors like age, BMI, and education level into its algorithm[20]. Uniquely, Macula Risk PGx includes a component called Vita Risk® which specifically looks at two gene variants (in CFH and ARMS2) to predict a patient’s response to nutritional supplements[21]. The idea behind Vita Risk is to identify those who may not benefit from (or could even be harmed by) zinc in the AREDS formulation – a concept we will revisit. Macula Risk is ordered through eye care professionals (ophthalmologists or optometrists); a patient provides a cheek swab in the doctor’s office, which is sent to the lab for analysis[18]. This test has been used as a decision aid for ophthalmologists, especially to predict which early-stage patients are at high risk of developing wet AMD in the future[19].
• Sequenom (LabCorp) – RetnaGene™: RetnaGene was a test developed by Sequenom (a genomics company in the US) focusing on the risk of choroidal neovascularization (wet AMD). It analyzed 13 single nucleotide polymorphisms (SNPs) in major AMD genes (like CFH, C2/CFB, ARMS2, etc.) and provided a risk score specifically for developing wet AMD within a given time frame[22]. Patients were categorized into low, medium, or high risk for progression to neovascular AMD based on this score[23]. The RetnaGene test could use a blood or saliva sample and was marketed to eye care providers similar to Macula Risk. However, as of now RetnaGene is no longer available – Sequenom’s diagnostics division was acquired by another company (LabCorp), and that test was eventually discontinued[24]. RetnaGene’s development was significant historically, as it was among the first to attempt personalized risk predictions for the type of AMD (dry vs. wet) a patient might get.
• Visible Genomics: Visible Genomics is a newer entrant (based in the USA, with a presence in Chicago) that offers AMD genetic testing services directly through their platform. By 2020, their test was noted as a “recently launched option” for AMD risk assessment alongside ArcticDx[25]. Visible Genomics provides two test types: an AMD iGuard Genetic Risk Test for those without AMD (to predict overall risk of developing the disease), and an AMD iGuard Progression Test for patients who already have early or intermediate AMD (to predict the risk of progressing to advanced stages)[26][27]. Like Macula Risk, these tests use a combination of DNA analysis (looking at key gene variants) and health factors (like age, smoking) to generate a personalized risk report[26]. Visible Genomics’ tests are ordered online and a saliva swab kit can be mailed to the patient (or facilitated through a participating doctor). The company emphasizes making results easy to understand for patients and doctors, and positioning their service as part of proactive eye care (they highlight that genetics account for ~70% of AMD risk, underlining the value of knowing one’s genetic status)[28][29]. Visible Genomics is an example of how genetic testing is becoming more accessible; however, like others, it is a predictive tool and the results need interpretation (often they encourage involving eye care providers to tailor monitoring based on the genetic risk).
• 23andMe – AMD Genetic Health Risk Report: 23andMe is a well-known direct-to-consumer genetic testing company. While their service is more general (covering ancestry and health traits), they do offer an FDA-authorized Health Predisposition report for Age-Related Macular Degeneration. This report is included in the 23andMe Health + Ancestry test kit[30]. It specifically analyzes the two most common genetic variants associated with AMD risk: CFH Y402H and ARMS2 A69S[31]. Based on whether a person has 0, 1, or 2 copies of the risk variants at those two sites, 23andMe provides an assessment of increased risk of developing AMD. The report might say, for example, “You have slightly increased risk of AMD” if one carries one of the risk alleles. It’s important to note that 23andMe’s test is limited to those two variants, whereas clinical tests (like Macula Risk) look at a broader panel. The company also provides educational context in the report, explaining that many factors contribute to AMD and that their test does not diagnose the disease[32]. Because 23andMe’s service is consumer-initiated, people can access this information without a doctor – which makes it convenient, but also underscores the need for individuals to perhaps seek guidance (from a doctor or genetic counselor) in interpreting the results. As of now, 23andMe is one of the few DTC companies with FDA clearance to provide an AMD risk report (after regulatory hurdles were overcome in the late 2010s).
• Asper Biogene (Asper Biotechnology): Asper Biogene is a genetic testing company based in Estonia that provides ophthalmic genetic tests worldwide. They offer an Age-Related Macular Degeneration genetic test, which is likely a sequencing panel covering genes implicated in AMD (and possibly some rarer macular dystrophies)[33]. According to a 2017 report, Asper’s test was available direct-to-consumer globally[24]. Such a panel might be more commonly used in research or in comprehensive eye genetics clinics. It could be useful for identifying rare variants or contributory genes in cases with strong family history. However, in routine practice it’s less frequently used than the above-mentioned targeted tests, partly due to cost and the complexity of interpretation.

In addition to these, in the early 2010s companies like deCODE Genetics (Iceland) and others experimented with offering AMD risk as part of broader genome scans[34]. The direct-to-consumer genetic testing market saw some turmoil around 2010 when the FDA temporarily halted health-related genetic reports for companies including 23andMe and deCODE, citing the need for regulatory review[35]. Since then, some tests have re-entered the market with regulatory compliance (like 23andMe’s), while others like deCODE’s are no longer directly offered. Today, if individuals want a comprehensive AMD genetic analysis, they typically either go through their eye care provider for tests like Macula Risk, or use a consumer service (23andMe) for a partial glimpse, or possibly obtain raw genomic data and use third-party tools. It’s also worth noting that academic medical centers and some specialized labs offer testing for inherited retinal diseases which can include certain macular degenerations – but those are aimed at rare conditions like Stargardt disease or Best disease, which are different from AMD.

Cost and Accessibility: The cost of AMD genetic testing can vary widely. Consumer tests like 23andMe cost on the order of \$200 (for the full health+ancestry package). Tests like Macula Risk or Visible Genomics are often a few hundred dollars and might not be covered by insurance, since at this time many insurers consider AMD genetic testing as not “medically necessary” (because it doesn’t yet definitively change treatment). Some eye clinics provide it as an out-of-pocket option for interested patients. Always, it is recommended to have genetic counseling or professional guidance alongside testing, so the individual fully understands the implications.

What Do Genetic Test Results Mean for You?

Undergoing genetic testing for AMD will yield one of a few possible outcomes, generally presented as risk categories or scores. Unlike a test for, say, an infectious disease (which is positive or negative), an AMD genetic test doesn’t give a yes/no answer – it gives an assessment of how your genetic makeup affects your likelihood of developing macular degeneration. Interpreting these results requires nuance. Let’s break down what the results might look like and their implications:

• High Risk Genetic Profile: If a test determines you fall into the highest risk category (for example, Macula Risk category 5, or a "high risk" genetic score), this means you have inherited several of the strong risk variants known to contribute to AMD[19]. Practically, this might be reported as “Your genetics indicate an X-fold increased risk of advanced AMD” or “You have a high genetic predisposition to AMD.” It is critical to understand that this is not a diagnosis and not a guarantee. Many people with “high-risk” genotypes do not develop blindness from AMD – they might only get intermediate drusen and never progress further[6]. What it does mean is that you and your eye doctor should be vigilant: early detection and prevention become top priorities. For someone in this situation, doctors would likely recommend: more frequent eye exams (for instance, annual dilated retinal exams, and prompt check-ups if subtle symptoms arise), home monitoring (like using an Amsler grid to self-test for any visual distortion that could indicate early wet AMD), and of course aggressive management of lifestyle risk factors. If you are a smoker, a high-risk genetic result is an extra wake-up call to quit immediately, as smoking multiplies the inherited risk several times over[36]. You may also discuss starting AREDS2 supplements at the appropriate stage of early AMD if it develops – though not everyone with high genetic risk will even have signs of AMD yet. In essence, a high-risk result arms you with knowledge to be proactive. Indeed, studies have shown that patients who learned they had a high genetic risk for AMD often adopted healthier behaviors – for example, in one study many started wearing UV-blocking sunglasses, eating more eye-healthy nutrients, or taking vitamins, and some stopped smoking following genetic counseling[37]. This suggests that knowing one’s genetic risk can motivate positive action, which is a beneficial outcome.
• Moderate or Average Risk Profile: Some people’s results come back as intermediate – perhaps indicating a modestly elevated risk (say 2x the general population) or around average risk. Remember that “average” still means one has some chance, since about 1 in 8 people after age 60 get AMD to some degree. If you are told your genetic risk is moderate, the take-home message is not much different from general public health advice: maintain regular eye exams and a healthy lifestyle, since you are not invulnerable. The difference is, if you have other risk factors (like a family history or you’re a smoker), those combined with moderate genetic risk could put you in a higher overall risk bracket. Genetic counselors will often present this comprehensively, sometimes using absolute risk. For example, they may explain, “The average American has about an X% lifetime risk of AMD; based on your genetic test and family history, your risk might be in the Y% range.” This can help contextualize the result. In practice, moderate-risk individuals should do all the same smart things: don’t smoke, eat a diet rich in green leafy vegetables and omega-3 fatty acids, maintain good blood pressure and weight, and perhaps take eye vitamins if recommended by a physician in the future. Those steps could help offset a good portion of the genetic risk[38][39]. In fact, one analysis predicted that adopting healthy behaviors could significantly cut down the probability of progressing to advanced AMD even for those genetically predisposed[38].
• Low Genetic Risk Profile: A result that shows few or none of the known risk variants might classify someone as “low genetic risk.” This can be reassuring – it means you did not inherit the major common risk factors for AMD. However, it does not mean you have zero chance of AMD. Aging itself is the biggest risk factor (everyone is at risk eventually if they live long enough), and there are other non-genetic factors (smoking, diet, etc.) that play a large role[40]. Plus, there may be undiscovered genetic factors, or rare variants not covered by the test, that you could have. So, a low-risk result should be interpreted as “no significant inherited predisposition detected.” The practical advice remains: continue with routine eye care and healthy lifestyle, because you still could develop AMD, especially in your later decades. One should not become complacent. For example, if a person with “low risk genes” is a heavy smoker, their risk could easily become higher than a non-smoker with high-risk genes – lifestyle can sometimes outweigh genetics in AMD. This interplay is something genetic counselors emphasize to ensure people don’t misinterpret a negative test as a free pass to engage in bad habits[7].
• Uncertain or Novel Findings: In comprehensive genetic testing (like full gene panel sequencing), sometimes a rare variant of uncertain significance might be found in an AMD-related gene. This is less common with focused AMD tests (which look only at known risk SNPs), but as more sequencing is done, it could happen. For instance, you might have a rare mutation in a complement gene that scientists aren’t sure about. In such cases, the report might label it as “Variant of Uncertain Significance (VUS)”, which means no clear action can be taken on it. Genetic counselors would explain that more research is needed and that result shouldn’t currently change medical management.

Genetic Counseling and Result Discussion: Because of the nuances above, professional guidance is key when you get AMD genetic test results. A genetic counselor or informed ophthalmologist will help synthesize your genetic risk with your other factors (age, family history, health habits, and clinical exam findings). They will also discuss the emotional impact of results. Some individuals feel anxiety after learning they have high-risk genes – fearing an “inevitable” vision loss[7]. Counseling can provide reassurance by reiterating that it’s not inevitable and highlighting what can be done (frequent monitoring can catch early changes, and treatments for AMD are improving). On the flip side, those with low-risk results might feel relief but perhaps guilt or confusion if other family members have disease. In either scenario, the counselor will address feelings and ensure that no one makes harmful choices (for instance, it would be dangerous for a “low-risk” person to decide they never need eye exams – that’s not true, since risk is reduced, not eliminated).

Lifestyle Interventions Informed by Genetics: One of the most constructive uses of genetic results is tailoring lifestyle and supplement recommendations. All AMD patients and at-risk individuals are advised on general good health practices (don’t smoke, eat a nutrient-rich diet including leafy greens and fish, exercise, control blood pressure, etc.)[36][8]. If genetic risk is high, there’s even more reason to rigorously follow these. In terms of supplements, the widely used AREDS/AREDS2 formula (high-dose vitamins C, E, zinc, copper, plus lutein and zeaxanthin) is recommended for those with intermediate AMD to slow progression. A controversial question has been whether genetic testing should guide the use of these supplements. Earlier studies suggested that certain genotypes (in CFH and ARMS2) might not benefit from zinc, or could even fare worse with zinc[41][42]. For example, one analysis found patients with two CFH risk alleles and no ARMS2 risk had better outcomes without zinc, whereas those with the opposite genotype did better withzinc[41]. This led companies like ArcticDx to include Vita Risk in their test, aiming to tell doctors which patients should get zinc or not. However, subsequent large analyses by independent groups (and the original AREDS2 research team led by Dr. Emily Chew) did not confirm a significant genotype-by-supplement interaction[43][10]. The American Academy of Ophthalmology (AAO) has reviewed this evidence and currently does not endorse routine genetic testing to tailor vitamin therapy, stating that there isn’t sufficient proof that using genetic info improves outcomes[44][10]. Therefore, most retina specialists still recommend AREDS2 supplements based on clinical exam (presence of intermediate AMD) rather than genetics. If you have had genetic testing, you can discuss it with your doctor – some physicians might choose to avoid zinc in a patient who happens to have the high-risk CFH genotype, while others abide by standard one-size-fits-all supplement advice until more definitive evidence emerges. This is a perfect example of how genetic results may influence a decision, but must be interpreted cautiously and in context of medical consensus.

Ethical and Personal Considerations: It’s worth noting that learning genetic risk can have personal implications beyond medical management. Some patients wonder if they should inform relatives – since if they have high risk variants, their siblings or children might carry them too. Genetic counselors can assist in how to communicate such information within families. Another consideration is the psychological burden; as Dr. Chew from the National Eye Institute cautioned, giving a patient a genetic risk number could cause needless anxiety or, conversely, false reassurance[7]. The key is understanding that genetic testing for AMD is optional and meant to inform, not to scare. The AAO’s official stance (as of 2019-2021) has been to avoid routine genetic testing for AMD in clinical practice until there’s a clear benefit proven – because they are concerned about these very issues of interpretation and utility[45]. They don’t say it should never be done, but that it should be used judiciously. So if you do get tested, doing it in conjunction with counseling (rather than on your own via the internet without any guidance) is highly recommended. This ensures you get the full benefit of the information without the pitfalls.

In summary, genetic test results for AMD provide a refined look at your risk profile, but they do not seal your fate. High-risk results call for heightened preventive measures and monitoring – which can truly make a difference, since early detection of conversion to wet AMD can preserve vision (we have treatments that work best when started early). Low-risk results, while comforting, are not a license to ignore eye health. Regardless of the outcome, the knowledge gained should be used positively: to motivate healthy lifestyle choices and inform personalized eye care plans. And as research evolves, these results might someday guide new preventative treatments – but at present, their main value is in risk awareness and education.

How Genetic Insights are Shaping AMD Treatment and Future Therapies

Understanding the genetic underpinnings of AMD isn’t just useful for risk prediction – it’s also fundamentally changing how we approach treatment, prevention, and future cures. Here we discuss how genes and gene-based knowledge contribute to current management of AMD and inspire emerging therapies, touching on prevention, early diagnosis, existing treatments, and what’s on the horizon.

1. Prevention and Early Diagnosis: The adage “knowledge is power” applies strongly here. If we know someone has a high genetic risk of AMD (for example, through family history or genetic testing), we can encourage preventative strategies years before any disease manifests. As noted, smoking cessation is the single most impactful modifiable factor – smokers have about 3–4 times the risk of AMD as non-smokers[46], so quitting smoking can considerably lower one’s risk even in the presence of bad genes. Diet and nutritional supplements are another area: while everyone should have a balanced diet, those at elevated risk might particularly benefit from diets rich in antioxidants (vitamins C, E), carotenoids (lutein, zeaxanthin found in green vegetables), and omega-3 fatty acids (from fish) which some studies suggest support macular health[47]. Indeed, the AREDS2 clinical trial showed that a specific high-dose nutrient formula could slow progression of intermediate AMD to advanced stages by about 25% over 5 years[48]. Genetic insight reinforces who should be especially diligent about such measures.

Early diagnosis is also aided by genetic awareness. While there is currently no approved preventive medication to take for AMD just because you have risky genes, what can be done is closer clinical surveillance. Eye doctors may advise at-risk patients to come in more frequently or to use home monitoring tools. For instance, the ForeseeHome™ device (an at-home digital monitoring system for detecting conversion to wet AMD) or simply regular Amsler grid self-checks can catch the very earliest signs of choroidal neovascularization. This is crucial because if wet AMD is caught at an early stage (before a lot of vision is lost), treatment can preserve central vision effectively. In short, genetic information can stratify patients into different monitoring protocols – those with high genetic (and family) risk warrant a more watchful approach, potentially catching any development of AMD at the earliest and most treatable point.

2. Current Treatments Influenced by Genetics: Once AMD has developed, treatment depends on the stage and subtype (dry vs. wet):

• For early or intermediate dry AMD, the main “treatment” is risk reduction. Here, knowledge of genetics doesn’t change the actual therapy, but it underscores the use of AREDS2 supplements for those with appropriate risk factors. As mentioned, while there was a hypothesis that one might personalize the supplement formula based on CFH/ARMS2 genotype (avoiding zinc in some patients), current evidence and expert guidelines do not support altering the AREDS regimen on the basis of genetic testing[10][49]. Therefore, all patients with moderate AMD are generally advised to take AREDS2 vitamins (which contain zinc, antioxidants, lutein, zeaxanthin) unless there’s a specific contraindication, regardless of genotype. That said, patients who happen to know their genotype should discuss with their doctor; some retina specialists may use that information in a nuanced way in the future if new studies emerge. For now, genetics doesn’t change the standard-of-care for supplement recommendation, but it’s an area of ongoing research.
• For neovascular (wet) AMD, the gold-standard treatment is anti-VEGF therapy – periodic injections into the eye of medications that block vascular endothelial growth factor, thereby shrinking the abnormal blood vessels and preventing further leakage or bleeding. Introduced in the mid-2000s, anti-VEGF drugs such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab have dramatically improved the prognosis of wet AMD, often stabilizing vision and sometimes even improving it[50]. So far, these treatments are prescribed based on clinical findings (the presence of choroidal neovascularization) and are not guided by genetics. However, genetics is starting to creep into this realm in a couple of ways. First, some studies have explored whether certain gene variants influence how well a patient responds to anti-VEGF (this field is called pharmacogenetics). For example, there have been investigations into whether polymorphisms in the VEGF gene or in complement genes affect the needed frequency of injections or the visual outcomes – but no clear, clinically actionable genetic predictor is in use yet. Second, and more direct, is the application of gene therapy to deliver anti-VEGF treatment, which we’ll discuss under future treatments. At present, every wet AMD patient, regardless of genetic background, is treated in largely the same way – with anti-VEGF injections, possibly supplemented by photodynamic therapy or laser in certain cases[50]. Genetic research has not yet produced a “personalized medicine” approach for choosing one anti-VEGF drug over another or altering dose based on DNA. It’s something scientists are looking at, but today the regimen is based on disease features and patient tolerance.
• For advanced dry AMD (geographic atrophy), until recently there was no medical treatment to reverse or halt it. However, thanks in part to genetic insights, new therapies have emerged. The discovery that complement system dysregulation is central to AMD (from CFH and other gene studies) directly led to the development of drugs that target the complement pathway. In 2023, the FDA approved the first-ever treatments for geographic atrophy: pegcetacoplan (brand name Syfovre™) and avacincaptad pegol (Izervay™). Pegcetacoplan is a complement C3 inhibitor, and avacincaptad pegol inhibits complement C5[51][52]. By blocking these proteins, which are part of the inflammatory cascade implicated in retinal cell death, these drugs have been shown to slow the progression of atrophy. They do not restore lost vision, but they can preserve vision longer by slowing the expansion of the atrophic areas by roughly 20–35%[53]. The development of these drugs was heavily influenced by genetic findings: the strong association of CFH and C3 variants with AMD pointed researchers to the complement pathway as a therapeutic target[54][55]. In fact, BrightFocus Foundation noted that earlier scientific research into complement’s role in AMD “laid the groundwork” for these treatments’ development[55]. This is a great example of going from gene discovery to drug: without the genetic clue that complement was involved, these treatments might not have been prioritized. Now, patients with geographic atrophy have options to potentially maintain their vision longer, and it’s a direct fruit of genetic and molecular research.

3. Future Directions – Emerging Research and Treatments:

·      Gene Therapy: One of the most promising frontiers is gene therapy for AMD and related retinal conditions. Gene therapy involves delivering genetic material into a patient’s cells to treat or prevent disease – often using a benign virus as a carrier. In late 2017, the first retinal gene therapy (Luxturna for a rare inherited blindness) was approved, igniting hope for applying similar techniques to more common diseases[56]. For AMD, a major gene therapy approach in trials is aimed at wet AMD: instead of giving injections every month, what if we could make the retina produce its own anti-VEGF? This is exactly what gene therapy trials like RGX-314 (by RegenxBio/AbbVie) and ADVM-022 (by Adverum) are attempting. RGX-314 uses an adeno-associated virus to deliver a gene that causes the eye’s cells to create a protein similar to ranibizumab (an anti-VEGF drug)[57][58]. The idea is a one-time surgical injection of the virus under the retina, turning the eye into a “bio-factory” that continuously makes the anti-VEGF drug on its own[57]. Early trials of RGX-314 have shown promising results – patients treated with gene therapy had a significant reduction (around 60–80% less) in the need for regular anti-VEGF injections, maintaining similar disease control[59]. As Dr. Charles Wykoff, a lead researcher, explained, this could potentially become a “one-and-done” treatment for wet AMD, freeing patients from the burden of frequent shots[60]. As of 2024, phase 3 trials are underway, and experts are hopeful that RGX-314 could become the first FDA-approved gene therapy for AMD in the near future[61]. This would be a milestone: treating a complex disease by inserting a helpful gene. While this doesn’t directly fix a patient’s inherited genes, it uses genetic technology to improve treatment delivery.

Gene therapy for dry AMD is a bit more challenging, since we’d need to address things like complement overactivation or retinal cell survival. Some experimental approaches include gene therapies to boost protective factors in the retina or to reduce complement activity locally. These are still largely in preclinical stages. But the success of complement inhibitors might spur development of gene-based methods to sustain complement inhibition with fewer injections (analogous to the wet AMD approach).

• Genetic Research into New Targets: Scientists continue to hunt for the remaining genetic factors in AMD (remember, known variants explain about half the heritability[12], so more are out there). They are also dissecting how existing known genes cause damage. Each new gene discovered offers a potential “druggable” target. For example, if a new gene variant affecting cholesterol transport is found to strongly drive AMD, perhaps a systemic medication that modifies cholesterol (beyond current statins, which have been inconsistently effective in studies) could be repurposed or developed. Another intriguing area is exploring protective genes – certain variants in, say, the APOE gene appear to decrease AMD risk (the APOE ε2 allele is thought to be protective, whereas ε4 might be risk-promoting). Understanding why some genes protect could lead to therapies that mimic those protective effects.
• Personalized Medicine and Pharmacogenomics: In the future, as data accumulates, it’s conceivable that treatment might become more individualized. For instance, perhaps one day genetic profiling will identify which patients are likely to respond better to a particular anti-VEGF drug or to an anti-complement therapy, and doctors could choose treatment accordingly. We are not there yet; current treatments are broadly effective across the board. But research (like the trials investigating if certain complement genotypes respond more to complement inhibitors) is ongoing. If successful, this could mean a truly personalized treatment plan: your genetic makeup could guide not just your risk management but also which medicine (or combination of medicines) will work best for you.
• Regenerative Medicine and Stem Cells: While not directly a genetic therapy, it’s worth mentioning that understanding the genetic triggers of retinal cell death guides regenerative approaches too. There are trials transplanting stem cell-derived retinal pigment epithelial (RPE) cells into areas of geographic atrophy, aiming to replace cells lost partly due to those genetic susceptibility pathways. If genes tell us someone’s at high risk of GA, in the future we might intervene earlier with cell therapy to patch the retina before it loses too many cells.
• Early Detection Tools: Genetics is also merging with technology to improve early detection. For example, researchers are developing polygenic risk scores combined with artificial intelligence analysis of retinal images to predict who will progress to advanced AMD. A high polygenic risk might flag a patient for optical coherence tomography (OCT) scans more often or enrollment in preventive trials. One could imagine a scenario where a middle-aged individual gets a genetic screen and retinal exam; if they have high-risk genes and subtle changes, they could start a preventative treatment trial (once those exist) decades before severe disease. This proactive approach is the ultimate goal – to use genetics not just to react to AMD, but to prevent the worst of it.

4. Ongoing Studies and Clinical Trials: There are numerous clinical trials worldwide focusing on AMD, many prompted by genetic findings. For instance, drugs that target the complement pathway (beyond the two approved ones) are still being tested – some aim at complement Factor D, others at C1, etc., trying to fine-tune the approach and minimize side effects. Trials like the LEAD study examined if a laser intervention could slow AMD in genetically susceptible people (results were mixed). There’s also the field of nutrigenomics – could a diet or supplement regimen be optimized to one’s genotype? Some studies are analyzing if people with certain genetic profiles benefit more from, say, higher omega-3 intake. While no tailored diet formulas exist yet beyond general recommendations, the research is heading in that direction.

In summary, genetic understanding has already had tangible impacts on AMD treatment, most clearly in the development of complement-inhibiting drugs for geographic atrophy[55]. It has also enabled risk stratification that encourages earlier and more frequent intervention, which indirectly improves outcomes (because catching wet AMD early and starting anti-VEGF can preserve vision that would’ve been lost if caught late). Looking forward, the hope is that genetic advances will continue to drive new therapies – from gene therapies that reduce treatment burden to possibly one day editing or silencing harmful genes. The ultimate dream is a world where no one goes blind from AMD: where we can identify high-risk individuals early (through genetics and screening), prevent disease progression with targeted lifestyle or pharmaceutical interventions, and treat any emerging pathology with state-of-the-art, long-lasting solutions. We are not quite there yet, but each year of research, often built on the genetic discoveries of the last two decades, brings us a step closer to that goal.

 

Questioned answered in this article:
AMD heredity & basic risk

·       Is macular degeneration genetic or environmental?

·       How much of AMD risk is inherited?

·       What are the chances I’ll get AMD if my parent has it?

·       Does AMD run in families?

·       Can AMD skip a generation?

·       Are dry and wet AMD both genetic?

·       Which genes are most linked to AMD (CFH, ARMS2/HTRA1, C3)?

·       Do different ethnicities have different genetic risks for AMD?

·       Is early-onset macular degeneration genetic or something else?

·       What’s the difference between AMD and inherited macular dystrophies?

Genetic counseling (what to expect)

·       What is genetic counseling for AMD and who should consider it?

·       How do I prepare for a genetic counseling appointment about AMD?

·       What questions should I ask a genetic counselor about AMD risk?

·       Can a genetic counselor help me decide whether to get tested for AMD?

·       Will genetic counseling tell me if my kids are at risk for AMD?

·       Does genetic counseling change my eye-care plan?

Should I get tested?

·       Should I get genetic testing for AMD if I have a family history?

·       At what age should you test for AMD risk genes?

·       Is AMD genetic testing recommended by the American Academy of Ophthalmology?

·       When does AMD genetic testing actually change management?

·       Can AMD genetic testing predict if I’ll get wet AMD?

·       Is there an FDA-authorized AMD genetic test?

·       Is 23andMe’s AMD report enough to know my risk?

·       Are there clinical AMD tests my eye doctor can order?

·       Is there a polygenic risk score for AMD?

What the tests look for & how they work

·       What genes are included in AMD genetic tests (CFH, ARMS2, HTRA1, C2/CFB, C3, CFI)?

·       What does CFH Y402H mean for my AMD risk?

·       What does ARMS2 A69S mean for my AMD risk?

·       Do AMD tests use saliva, cheek swab, or blood?

·       What’s the difference between SNP genotyping and NGS panels for AMD?

·       Do AMD tests check mitochondrial variants?

·       How accurate are AMD risk tests?

·       What’s the turnaround time for AMD genetic testing?

Interpreting results

·       My AMD genetic test says “high risk”—what should I do next?

·       My results show “average risk”—does that change anything?

·       My results show “low risk”—do I still need eye exams?

·       What is a “variant of uncertain significance” (VUS) in AMD testing?

·       Can genetic results tell me if I’ll respond to treatment?

·       How often should I be monitored if I’m high genetic risk but have no symptoms?

Lifestyle, prevention, and supplements

·       If I have high-risk AMD genes, what lifestyle changes help most?

·       Does smoking interact with AMD risk genes?

·       Which diet is best if I have genetic risk for AMD (Mediterranean, leafy greens, omega-3)?

·       Do blue-light or UV-blocking lenses matter more if I’m high genetic risk?

·       Should my genotype change the AREDS2 vitamins I take?

·       Is zinc in AREDS helpful or harmful for some genotypes?

·       Can genetics predict progression from early AMD to geographic atrophy?

Counseling for family planning & relatives

·       Should my siblings or adult children get AMD genetic testing?

·       What’s the chance my child will inherit my AMD risk genes?

·       How do I talk to family about shared AMD genetic risk?

·       Are there privacy or insurance concerns when sharing AMD genetic results?

Cost, access, and privacy

·       How much does AMD genetic testing cost?

·       Is AMD genetic testing covered by insurance?

·       Do I need a doctor’s order for AMD genetic testing?

·       Are direct-to-consumer AMD tests reliable?

·       Will AMD genetic results affect my insurance or employment (GINA, privacy)?

Tests & companies (informational queries)

·       Which companies offer AMD-specific genetic testing?

·       ArcticDx Macula Risk vs. other AMD tests—what’s the difference?

·       What is Visible Genomics AMD iGuard?

·       Does 23andMe test for AMD risk genes CFH and ARMS2?

·       Are hospital or academic panels better than consumer AMD tests?

Treatment now & next (gene-informed)

·       Do complement pathway genes (CFH/C3) matter for new GA drugs?

·       Do pegcetacoplan (Syfovre) or avacincaptad pegol (Izervay) work better for certain genotypes?

·       Can genetics predict who progresses to wet AMD?

·       Is there gene therapy for AMD right now?

·       What is RGX-314 gene therapy for wet AMD?

·       Will gene editing (CRISPR) ever be used for AMD?

·       Do my AMD genes affect how often I need anti-VEGF injections?

Imaging, AI & early detection

·       Can AI plus genetics predict AMD before symptoms?

·       Should high-risk patients use home monitoring (Amsler grid, ForeseeHome)?

·       How often should I get OCT scans if I’m high genetic risk?

Distinguishing AMD from inherited macular diseases

·       How do I tell AMD from Stargardt or Best disease?

·       When is genetic testing essential (juvenile-onset macular disease vs AMD)?

·       Does a family history of “macular disease” always mean AMD?

 

 

References

·      National Human Genome Research Institute – “Genetic Counseling” (August 14, 2025 update)[1][2].

·      Visible Genomics – The Role of Genetics in Macular Degeneration (Blog article, Feb 1, 2024)[11][16].

·      Macular Disease Foundation Australia – Risk Factors for AMD (Web page)[62][36]; and Genetic Testing for Macular Disease (Web page, 2021)[5][63].

·      American Academy of Ophthalmology – AAO Recommendations on genetic testing (2014), cited in Retina Specialist 2015[44] and Review of Optometry 2020[45].

·      Liu, Y., Seddon, J.M., Sobrin, L. – “Genetic Testing for Age-Related Macular Degeneration: With great promise come many controversies” in Retina Specialist (June 15, 2015)[13][44].

·      Kim, I.K. – “Genetic Testing for AMD Inches Forward” in Review of Ophthalmology (July 5, 2012)[18][64].

·      Scott, I.U., Kovach, J.L. – “Using Genetics to Guide AMD Therapy: Are We There Yet?” in Retinal Physician (Jan 1, 2017)[12][20].

·      Nalley, C. – “Genetics in Eye Care: DNA Leads the Way” in Review of Optometry (Oct 15, 2020)[25][10].

·      McCarty, C.A. et al. – Study on patient responses to AMD genetic testing, summarized in “Genetic Tests Inspire Lifestyle Changes” in Review of Optometry (Apr 6, 2018)[37].

·      23andMe – Is Age-Related Macular Degeneration Genetic? (23andMe Health Predispositions Report information)[30][31].

·      BrightFocus Foundation – “Second Geographic Atrophy Treatment Receives FDA Approval” (News article, Aug 8, 2023)[53][55].

·      Houston Methodist – “RGX-314 Gene Therapy Trial Shows Promise in Treating Wet AMD” (News blog, Aug 13, 2024)[60][61].

·      National Eye Institute – AREDS/AREDS2 research findings on supplements (2013), as referenced by Healthline (2024)[48][50].

·      Additional References: MedlinePlus – Age-related Macular Degeneration Genetics[65]; JAMA Ophthalmology – Twin study on AMD heritability (Klein et al. 2005)[66]; and ClinicalTrials.gov – ongoing trials in AMD genetics and therapies (accessed 2025).

[1] [2] Genetic Counseling

https://www.genome.gov/genetics-glossary/Genetic-Counseling

[3] [5] [6] [63] Genetic testing for macular disease Macular Disease Foundation Australia Macular Disease Foundation Australia

https://www.mdfoundation.com.au/about-macular-disease/genetic-testing/genetic-testing-macular-disease/

[4] [8] [36] [46] [62] Risk Factors for Age-Related Macular Degeneration | Macular Disease Foundation Australia

https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/risk-factors-for-amd/

[7] [10] [25] [45] [49] [56] Genetics in Eye Care: DNA Leads the Way

https://www.reviewofoptometry.com/article/genetics-in-eye-care-dna-leads-the-way

[9] [13] [14] [15] [41] [42] [43] [44] Genetic Testing for Age-Related Macular Degeneration

https://www.retina-specialist.com/article/genetic-testing-for-agerelated-macular-degeneration

[11] [16] A Comprehensive Guide to Understanding, Managing, and Treating AMD — Visible Genomics

https://www.visiblegenomics.com/focusing-on-amd-blog/the-role-of-genetics-in-macular-degeneration

[12] [17] [20] [21] [24] [35] Using Genetics to Guide AMD Therapy: Are We There Yet? | Retinal Physician

https://retinalphysician.com/issues/2017/january/using-genetics-to-guide-amd-therapy-are-we-there-yet/

[18] [19] [22] [23] [34] [54] [64] Genetic Testing for AMD Inches Forward

https://www.reviewofophthalmology.com/article/genetic-testing-for-amd-inches-forward

[26] [27] [28] [29] AMD genetic testing for Age-Related Macular Degeneration

https://www.visiblegenomics.com/

[30] [31] [32] [40] Is AMD Genetic? Genetic Testing for AMD - 23andMe

https://www.23andme.com/topics/health-predispositions/amd/?srsltid=AfmBOorkyQcU5fe3ewwJYqEECP0UVBSyMY8NxvEYBNDFUcC7_yy2j1i1

[33] Age-Related Macular Degeneration – AMD | Asper Biogene

https://www.asperbio.com/asper-ophthalmics/age-related-macular-degeneration-amd/genetic-testing/ngs-panel

[37] Genetic Tests Inspire Lifestyle Changes

https://www.reviewofoptometry.com/article/genetic-tests-inspire-lifestyle-changes

[38] Quantifying Effects of Lifestyle Changes on Progression ... - medRxiv

https://www.medrxiv.org/content/10.1101/2025.06.18.25329367v1.full-text

[39] Quantifying Effects of Lifestyle Changes on Progression to ...

https://www.medrxiv.org/content/10.1101/2025.06.18.25329367v1

[47] [48] [50] How Do Genetics Play a Role in Age-Related Macular Degeneration?

https://www.healthline.com/health/is-macular-degeneration-hereditary

[51] [52] [53] [55] Second Geographic Atrophy Treatment Receives FDA Approval

https://www.brightfocus.org/news/second-geographic-atrophy-treatment-receives-fda-approval/

[57] [58] [59] [60] [61] RGX-314 Gene Therapy Trial Shows Promise in Treating Wet Macular Degeneration

https://www.houstonmethodist.org/leading-medicine-blog/articles/2024/aug/rgx-314-gene-therapy-trial-shows-promise-in-treating-wet-macular-degeneration/

[65] Genetically predisposed? Patients want to know AMD risk, make ...

https://www.aoa.org/news/clinical-eye-care/diseases-and-conditions/genetic-testing-for-amd

[66] The US Twin Study of Age-Related Macular Degeneration

https://jamanetwork.com/journals/jamaophthalmology/fullarticle/416900